Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences, Inc. (GILD) Presents at 2022 Wells Fargo Healthcare Conference - (Transcript)
01:32pm, Thursday, 08'th Sep 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) 2022 Wells Fargo Healthcare Conference September 8, 2022 10:25 AM ET Company Participants Andrew Dickinson - CFO Conference Call Participants Mohit Bansal - Wells
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
02:18pm, Wednesday, 07'th Sep 2022
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
3 Great Dividend Stocks to Buy in September
06:08am, Saturday, 03'rd Sep 2022
One word describes these three stocks and their dividends -- solid.
You can start to dip your toes into biotech here, says Jefferies' Yee
04:25pm, Friday, 02'nd Sep 2022
Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.
Gilead Sciences: Don't Miss The Transformation
05:37am, Thursday, 01'st Sep 2022
Gilead Sciences is focused on building up its new businesses, which, despite struggles in the area, are growing at break-neck paces. The company has a single-digit P/E ratio and an almost 5% dividend
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
01:32pm, Tuesday, 30'th Aug 2022
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Monday, 29'th Aug 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Co
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
01:33pm, Monday, 22'nd Aug 2022
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-v
Gilead Sciences: Checking The 4 Pillars Of A Value Stock
04:33am, Monday, 22'nd Aug 2022
In the current market environment, investors are arguably well advised to overweight quality and underweight growth. Gilead Sciences trades attractively at a one-year forward P/E below x10. And amidst
Gilead Has To Keep Playing The Exclusion Game
11:52am, Sunday, 21'st Aug 2022
After a long period of flat sales and Biktarvy ramped up while cannibalising its HIV peers, finally HIV produces nice growth. However, now Veklury, the vaunted first COVID-19 treatment, is the black s
Gilead Vs. Johnson & Johnson: Who's The Better Dividend Stock?
11:06am, Sunday, 21'st Aug 2022
Johnson & Johnson is a quintessential dividend growth stock. However, its spinoff plan creates some uncertainties ahead. For investors looking for alternative dividend ideas in the healthcare space, G
Gilead Is Too Cheap To Ignore And Set To Soar
09:30am, Sunday, 21'st Aug 2022
Gilead has leading positions in important drug categories, superior profitability, and is actively repurchasing shares. While there are some risks around declining HCV sales, they are more than offset
The 'Halftime Report' investment committee offers its dividend picks
01:40pm, Friday, 19'th Aug 2022
Favorite dividend stock picks right now. With CNBC's Frank Holland the the 'Halftime Report' investment committee, Rob Sechan, Kevin O'Leary, Richard Saperstein and Shannon Saccocia
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
09:02am, Thursday, 18'th Aug 2022
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
